In NSCLC for example, high soluble PDL-1 is associated with adverse prognosis, and studies in melanoma suggest it could even be utilized as a dynamic predictor of durable efficacy to checkpoint inhibitors (Hofman et al., 2019). The gene discussed is CD274; the disease is melanoma.